Share this article
Share this article
SHANGHAI, Dec. 14, 2020 /PRNewswire/ 3SBio Inc. ( 3SBio ) s subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. ( Sunshine Guojian ) and Verseau Therapeutics, Inc. ( Verseau ) today announced the selection of a monoclonal antibody targeting VSIG4, as a licensed program under their partnership agreement focused on the development and commercialization of novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. This is the second licensed program under the partnership agreement signed between the parties in 2019. The first licensed program was granted by Verseau to Sunshine Guojian for VTX-0811, a novel PSGL-1-targeted antibody in the field of immuno-oncology, on November 18, 2019.